Browsing Tag
BAFF APRIL inhibition
1 post
Aurinia Pharmaceuticals posts positive Phase 1 data for aritinercept (AUR200) with implications for autoimmune disease treatment
Aurinia Pharmaceuticals reveals strong Phase 1 data for aritinercept (AUR200), signaling promise in autoimmune disease therapeutics. Read full clinical insights.